Lester Jenkins v. BP Exploration & Production Inc.

Court of Appeals for the Eleventh Circuit·Decided October 18, 2024·No. 23-11538·Published

Opinion

[PUBLISH]

In the

United States Court of Appeals For the Eleventh Circuit

No. 23-11535

In Re: DEEPWATER HORIZON BELO CASES,

BELO PLAINTIFFS, Plaintiffs,

LESTER JENKINS, DWIGHT SIPLES, Interested Parties-Appellants, versus BP EXPLORATION & PRODUCTION, INC., BP AMERICA PRODUCTION COMPANY,

Defendants-Appellees.

2 Opinion of the Court 23-11535

Appeal from the United States District Court for the Northern District of Florida D.C. Docket No. 3:19-cv-00963-MCR-HTC

No. 23-11538

LESTER EUGENE JENKINS, Plaintiff-Appellant,

DWIGHT SIPLES, Interested Party-Appellant, versus BP EXPLORATION & PRODUCTION INC, BP AMERICA PRODUCTION COMPANY,

Defendants-Appellees.

Appeal from the United States District Court for the Northern District of Florida

23-11535 Opinion of the Court 3

D.C. Docket No. 5:19-cv-00260-MCR-HTC

No. 23-11539

DWIGHT SIPLES, JR., Plaintiff-Appellant,

LESTER JENKINS, Interested Party-Appellant, versus BP EXPLORATION & PRODUCTION, INC., BP AMERICA PRODUCTION COMPANY,

Defendants-Appellees.

Appeal from the United States District Court for the Northern District of Florida D.C. Docket No. 5:19-cv-00310-MCR-HTC

4 Opinion of the Court 23-11535

Before WILLIAM PRYOR, Chief Judge, and LUCK and ED CARNES, Circuit Judges. WILLIAM PRYOR, Chief Judge:

This appeal asks whether the district court abused its discretion when it excluded expert opinion testimony about general causation in a suit related to the Deepwater Horizon oil spill. Lester Jenkins and Dwight Siples Jr. participated in the cleanup of that spill. And both men complain that their exposure to crude oil and dispersants during the cleanup caused chronic sinusitis. Because neither crude oil nor dispersants are known toxins, Jenkins and Siples needed to prove general causation. Their expert witnesses opined that a causal relationship existed between the cleanup work and chronic sinusitis. But the district court ruled that neither expert identified a minimal level of exposure at which crude oil, its dispersants , or the chemicals associated with either are hazardous to human beings. And it found that the experts failed to identify a statistically significant association between the chronic conditions and exposure to crude oil, assess various studies’ limitations, or meaningfully consider causal factors. Because the district court did not abuse its discretion, we affirm the summary judgment against Jenkins and Siples.

I. BACKGROUND

This appeal rises and falls on the admission of expert evidence and the scientific methodologies that ground toxic-tort actions . So we begin with a short primer on those methods and the

23-11535 Opinion of the Court 5

burdens of proof relevant to these suits. Then we turn to the facts and procedural history for this appeal.

A. A Primer on Toxic Torts Toxic-tort actions come in two forms. In the first, the medical community already recognizes that a specific “agent”—i.e., a substance external to the human body (think drugs, chemicals, minerals)—is toxic and capable of “caus[ing] the type of harm a plaintiff alleges.” McClain v. Metabolife Int’l, Inc., 401 F.3d 1233, 1239 (11th Cir. 2005). In these actions, the parties battle over specific causation only: that is, whether the agent caused a specific plaintiff ’s disease. Id. In the second, the medical community does not recognize an agent as both toxic and capable of causing the kind of injury a plaintiff alleges. Id. Plaintiffs in these actions must establish both general and specific causation.

General causation asks “whether an agent increases the incidence of disease in a group and not whether the agent caused any given individual’s disease.’’ Michael D. Green et al., Reference Guide on Epidemiology, in REFERENCE MANUAL ON SCIENTIFIC EVIDENCE 549, 623 (Fed. Jud. Ctr., 3d ed. 2011). In toxic-tort actions, plaintiffs prove general causation through epidemiological evidence, dose- response relationship, and background risk of disease. Chapman v. Procter & Gamble Distrib., LLC, 766 F.3d 1296, 1308 (11th Cir. 2014). Because these three kinds of evidence underpin our general-causation precedent, we describe each briefly.

Epidemiology. Epidemiology “studies the incidence, distribution , and [cause] of disease in human populations.” Green, supra, at

6 Opinion of the Court 23-11535

551. Experts who rely on epidemiological evidence to establish general causation assess that evidence in two steps. To start, they ask whether the evidence “reveal[s] an association between an agent and [a] disease.” Id. at 554. To identify an association, experts must rule out alternative explanations, by asking, for example, whether a potential association resulted from limitations in the study, like chance or bias. Id. at 554, 572. Experts also ask “whether the association reflects a true cause-effect relationship.” Id. at 554, 597. In this context, causation means something akin to but-for cause: exposure to a toxic agent is “a necessary link in [the] chain of events” that led to the disease. Id. at 597–98.

To decide whether a particular study supports a causal inference , experts consider the nine factors developed by Sir Austin Bradford Hill: (1) temporal relationship; (2) strength of the association ; (3) dose-response relationship; (4) replication of the findings; (5) biological plausibility; (6) consideration of alternative explanations ; (7) cessation of exposure; (8) specificity of the association; and (9) consistency with other knowledge. Id. at 600 (citing Austin Bradford Hill, The Environment and Disease: Association or Causation?, 58 Proc. Royal Soc’y Med. 295, 295–300 (1965)). No factor is dispositive . And “[n]o algorithm exists for applying the Hill guidelines.” Restatement (Third) of Torts: Liability for Physical and Emotional Harm § 28 cmt. c(3) (Am. L. Inst. 2010). Instead, their application requires judgment. Id.

Dose-Response Relationship. At a high level, “a dose-response relationship means the greater the exposure, the greater the risk of

23-11535 Opinion of the Court 7

disease.” Green, supra, at 603. At a more granular level, the term describes “a relationship in which a change in amount, intensity, or duration of exposure to [a chemical] is associated with a change— either an increase or decrease—in risk.” McClain, 401 F.3d at 1241– 42 (citation and internal quotation marks omitted). This relationship is “the hallmark of basic toxicology” because “all substances potentially can be toxic.” Chapman, 766 F.3d at 1307. Most “low dose exposures—even for many years—will have no consequence [s] at all.” McClain, 401 F.3d at 1242 (citation and internal quotation marks omitted). This fact makes “[d]ose . . . the single most important factor to consider in evaluating whether an alleged exposure caused a specific adverse effect.” Id. (citation and internal quotation marks omitted).

Background Risk of Disease. Background risk of disease simply means “the risk . . . the general public ha[s] of suffering the disease or injury that [a] plaintiff alleges without exposure to the drug or chemical in question.” Id. at 1243. This risk assessment covers all “causes of a disease, whether known or unknown, excluding the drug or chemical in question.” Id. The epidemiological and toxicological methods discussed focus on whether an association exists between a specific agent or disease. But without background risk as a baseline, determining whether an association is anything more than a coincidence becomes difficult, if not impossible. Chapman, 766 F.3d at 1307–08.

8 Opinion of the Court 23-11535

Free access — add to your briefcase to read the full text and ask questions with AI

Lester Jenkins v. BP Exploration & Production Inc., (11th Cir. 2024).

Lester Jenkins v. BP Exploration & Production Inc. (Lester Jenkins v. BP Exploration & Production Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Richard Junior Frazier
387 F.3d 1244 (Eleventh Circuit, 2004)
Rink v. Cheminova, Inc.
400 F.3d 1286 (Eleventh Circuit, 2005)
Johnny C. McClain v. Metabolife International, Inc
401 F.3d 1233 (Eleventh Circuit, 2005)
United States v. Ronald Keith Brown
415 F.3d 1257 (Eleventh Circuit, 2005)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
United States v. Irey
612 F.3d 1160 (Eleventh Circuit, 2010)
Douglas C. Kilpatrick v. Breg, Inc.
613 F.3d 1329 (Eleventh Circuit, 2010)
Mitchell v. Gencorp Inc.
165 F.3d 778 (Tenth Circuit, 1999)
Wright v. Willamette Industries, Inc.
91 F.3d 1105 (Eighth Circuit, 1996)
Seamon Ex Rel. Estate of Seamon v. Remington Arms Co.
813 F.3d 983 (Eleventh Circuit, 2016)
Teresa Taylor v. Mentor Worldwide, LLC
940 F.3d 582 (Eleventh Circuit, 2019)
United States v. David Ming Pon
963 F.3d 1207 (Eleventh Circuit, 2020)
Westberry v. Gislaved Gummi AB
178 F.3d 257 (Fourth Circuit, 1999)